| Identification | Back Directory | [Name]
Gontivimab | [CAS]
1257358-38-5 | [Synonyms]
Gontivimab
Research Grade Gontivimab
Research Grade Gontivimab (DVV02806) |
| Hazard Information | Back Directory | [Uses]
Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung[1]. | [in vivo]
Gontivimab (1-68 mg/kg; intranasal administration or nebulization) reduces the RSV load in the nose and lungs in rats[1]. | Animal Model: | Rats (RSV Tracy)[1] | | Dosage: | 1-68 mg/kg | | Administration: | Intranasal administration or nebulization; once (day 2 or day 3) or twice (day 2 and day 3) | | Result: | Resulted in significant viral load reductions in the lungs ranging. |
| [References]
[1] Detalle L, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. DOI:10.1128/AAC.01802-15 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|